Structure Therapeutics, Inc. Sponsored ADR (GPCR)
NASDAQ:GPCR
Want to see GPCR full AI Analyst Report?
GPCR Stock Chart & Stats
$50.75
-$0.32(-1.18%)
At close: 4:00 PM EST
$50.75
-$0.32(-1.18%)
Day’s Range― - ―
52-Week Range$15.80 - $94.90
Previous CloseN/A
Volume219.80K
Average Volume (3M)1.00M
Market Cap
$3.05B
Enterprise Value$1.68B
Total Cash (Recent Filing)$1.45B
Total Debt (Recent Filing)$6.49M
Price to Earnings (P/E)31.2
Beta1.07
Next Earnings
May 07, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.40
Shares Outstanding70,841,810
10 Day Avg. Volume868,252
30 Day Avg. Volume1,002,718
Financial Highlights & Ratios
PEG Ratio-11.37
Price to Book (P/B)2.72
Price to Sales (P/S)0.00
P/FCF Ratio-18.23
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.45K
Enterprise Value/Ebitda-10.67
Forecast
1Y Price Target
$107.77Price Target Upside112.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-1.49
Revenue Forecast (FY)$7.14M
Bulls Say, Bears Say
Bulls Say
Commercial And Manufacturing AdvantagesLow cost of goods and scalable manufacturing combined with a potential pricing shift toward chronic disease management could expand the addressable patient base and improve long-term commercial prospects for an oral agent.
Efficacy DifferentiationClinical data show higher dosing of aleniglipron can produce continued and meaningful weight loss without an obvious plateau, supporting the potential for injectable-like efficacy from an oral therapy.
Tolerability And Dosing StrategyOpen-label and extension results indicate that starting at a low dose with slower titration markedly improves tolerability and reduces nausea and vomiting, which could lower treatment discontinuation rates in later studies.
Bears Say
Business Development And Execution RiskLack of visible business development activity ahead of an advanced trial start would be a material downside risk that could constrain partnership opportunities and valuation upside.
Clinical Data UncertaintyAvailable trial data derive from relatively small patient cohorts, creating uncertainty about how efficacy and tolerability will translate in larger pivotal studies and potentially weighing on investor confidence.
Competitive Pressure From InjectablesHigh‑potency injectable therapies retain a mechanistic advantage and are likely to remain market leaders, which could limit initial market share capture by oral competitors.
Structure Therapeutics, Inc. Sponsored ADR News
GPCR FAQ
What was Structure Therapeutics, Inc. Sponsored ADR’s price range in the past 12 months?
Structure Therapeutics, Inc. Sponsored ADR lowest stock price was $15.80 and its highest was $94.90 in the past 12 months.
What is Structure Therapeutics, Inc. Sponsored ADR’s market cap?
Structure Therapeutics, Inc. Sponsored ADR’s market cap is $3.05B.
When is Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date?
Structure Therapeutics, Inc. Sponsored ADR’s upcoming earnings report date is May 07, 2026 which is in 2 days.
How were Structure Therapeutics, Inc. Sponsored ADR’s earnings last quarter?
Structure Therapeutics, Inc. Sponsored ADR released its earnings results on Feb 26, 2026. The company reported $0.175 earnings per share for the quarter, beating the consensus estimate of -$0.057 by $0.232.
Is Structure Therapeutics, Inc. Sponsored ADR overvalued?
According to Wall Street analysts Structure Therapeutics, Inc. Sponsored ADR’s price is currently Undervalued.
Does Structure Therapeutics, Inc. Sponsored ADR pay dividends?
Structure Therapeutics, Inc. Sponsored ADR does not currently pay dividends.
What is Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate?
Structure Therapeutics, Inc. Sponsored ADR’s EPS estimate is -0.35.
How many shares outstanding does Structure Therapeutics, Inc. Sponsored ADR have?
Structure Therapeutics, Inc. Sponsored ADR has 70,841,810 shares outstanding.
What happened to Structure Therapeutics, Inc. Sponsored ADR’s price movement after its last earnings report?
Structure Therapeutics, Inc. Sponsored ADR reported an EPS of $0.175 in its last earnings report, beating expectations of -$0.057. Following the earnings report the stock price went down -2.734%.
Which hedge fund is a major shareholder of Structure Therapeutics, Inc. Sponsored ADR?
Currently, no hedge funds are holding shares in GPCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Structure Therapeutics, Inc. Sponsored ADR Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.77 (112.36% Upside)
$107.77 (112.36% Upside)
Blogger Sentiment
Bullish
GPCR Sentiment 83%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 57.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 9.9%
Last 30 Days ▲ 9.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.22%
12-Months-Change
Fundamentals
Return on Equity
-14.55%
Trailing 12-Months
Asset Growth
75.34%
Trailing 12-Months
Company Description
Structure Therapeutics, Inc. Sponsored ADR
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.
GPCR Stock 12 Month Forecast
Average Price Target
$107.77
▲(112.36% Upside)
Technical Analysis
Ownership Overview
10.11% Insiders
24.38% Mutual Funds
0.31% Other Institutional Investors
63.10% Public Companies and Individual Investors